Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Starpharma Holdings Receives $7.7m R&D Tax Incentive Refund

20 Jan 2022  |  08:55:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Starpharma receives $7.7M R&D tax incentive refund

Starpharma Holdings announced that it has received a $7.7m research and development (R&D) tax incentive refund related to the Company's Australian and international R&D expenses from the 2021 financial year. The tax refund is for eligible R&D activities across its portfolio, including the Company's DEP oncology products and VIRALEZE antiviral nasal spray.

Please click here for full details

See more ASX300 News Announcements